Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Affiliations

• ¹ Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
• ² Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
• ³ Department of Allergy and Clinical Immunology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
• ⁴ Department of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• ⁵ Versiti, Translational Glycomics Center, Blood Research Institute, Milwaukee, WI, USA.
• ⁶ Departments of Biochemistry and Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
• ⁷ Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
• ⁸ Pfizer Inc., New York, NY, USA.
• ⁹ Pfizer Inc., La Jolla, CA, USA.
• ¹⁰ Pfizer R & D UK Ltd., Kent, UK.
• ¹¹ Pfizer Ltd., Surrey, UK.
• ¹² Pfizer Inc., Collegeville, PA, USA.
• ¹³ Pfizer Inc., Groton, CT, USA.
• ¹⁴ Pfizer Inc., Collegeville, PA, USA. [email protected].